HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Arabia, F.A. Articles by Kormos, R. Search for Related Content PubMed PubMed Citation Articles by Arabia, F.A. Articles by Kormos, R.

Eur J Cardiothorac Surg 1997;11:S5-S10
© 1997 Elsevier Science NL

International experience with the CardioWest total artificial heart as a bridge to heart transplantation

University of Arizona, Health Sciences Center, Tucson, AZ, USA

^_* Corresponding author.

As the number of potential heart donors remains constant and the number of potential recipients continuous to increase, the need for circulatory devices to bridge patients becomes more important. The CardioWest total artificial heart (TAH) is a pneumatic, implantable system that totally replaces the failing ventricles. It has been utilized worldwide as a bridge to heart transplantation in 79 patients. There were 73 males and six females who received the TAH. Currently three patients remain on the device waiting for transplantation. A total of 55 patients (70%) were transplanted of which 50 survived (91% of patients transplanted) and were discharged home. Idiopathic/dilated cardiomyopathy was the most common etiology followed by ischemic cardiomyopathy. The mean duration of implant was 34 days (range 0–186 days) and the mean age of the group was 45 years (range 16–62 years). Twenty-one patients died while on the device. Multiple organ failure was the major cause of death. There were a total of 255 complications in this group that included reoperation, and bleeding, hepatic failure, renal failure, respiratory failure, neurologic events, thromboembolic events, infections, device malfunction, and fit complications. This represented a mean complication rate of three events per patient. The survival rate for the CardioWest TAH of 91% of the patients who reached transplantation is an improvement over that of the Symbion registry (55% of those transplanted) probably as a result of a better patient selection and better control of the coagulation system. These results are also comparable to those survival results obtained with other biventricular and left ventricular assist devices currently available.

This article has been cited by other articles:

				J. C. Roussel, T. Senage, O. Baron, C. Perigaud, O. Habash, J. C. Rigal, M. Treilhaud, J. N. Trochu, P. Despins, and D. Duveau CardioWest (Jarvik) Total Artificial Heart: A Single-Center Experience With 42 Patients Ann. Thorac. Surg., January 1, 2009; 87(1): 124 - 130. [Abstract] [Full Text] [PDF]

				S. Aggarwal, F. Cheema, M. C. Oz, and Y. Naka Long-Term Mechanical Circulatory Support Card. Surg. Adult, January 1, 2008; 3(2008): 1609 - 1628. [Full Text]

				O.H. Frazier, T. J. Myers, and I. Gregoric Total Artificial Heart Card. Surg. Adult, January 1, 2008; 3(2008): 1629 - 1638. [Full Text]

				O. H. Frazier, N. A. Shah, and T. J. Myers Total Artificial Heart Card. Surg. Adult, January 1, 2003; 2(2003): 1507 - 1514. [Full Text]

				F. W. H. Sutherland and J. E. Mayer Jr. Tissue engineering for cardiac surgery Card. Surg. Adult, January 1, 2003; 2(2003): 1527 - 1536. [Full Text]

				M. Loebe, T. Drews, E. Potapov, D.-V. Ngo, R. zu Dohna, and R. Hetzer Device selection in mechanical circulatory support Perfusion, July 1, 2000; 15(4): 313 - 318. [PDF]